Biocon’s arm gets USFDA’s nod for Everolimus Tablets

11 Apr 2025 Evaluate

Biocon’s wholly owned subsidiary -- Biocon Pharma has received approval for its ANDA for Everolimus Tablets from the U.S. Food and Drug Administration (USFDA), in strengths of 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg. Everolimus is a prescription medication that is indicated for the prophylaxis of organ rejection in adult patients, and in kidney and liver transplantation.

The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

398.05 -3.35 (-0.83%)
24-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1737.50
Dr. Reddys Lab 1266.35
Cipla 1496.35
Zydus Lifesciences 917.45
Lupin 2109.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×